Survey Reveals Adalimumab-atto Maintains Leadership in US Adalimumab Biosimilars Market
Spherix Global Insights, a leading provider of market research, conducted a survey using a sample of 81 rheumatologists, 83 gastroenterologists, and 80 dermatologists to evaluate adoption rates, experiences, concerns, and future expectations of biosimilars.
Amgen tipped to keep Otezla market share in fight with BMS’ Sotyktu, leaving opportunity for J&J
Amgen’s $13.4 billion Otezla bet can withstand competition from Bristol Myers Squibb’s Sotyktu. That is the conclusion of analysts at Spherix Global Insights, who found Amgen is holding on to its market share and largely limiting BMS’ growth to the conversion of users of injectable biologics. BMS sold Otezla to Amgen to secure regulatory clearance for […]
Another Medicine to Stop Migraine in its Tracks – Zavzpret™ is Now Available, but Where will Neurologists use it?
Will Pfizer’s marketing power help Zavzpret™ rapidly gain share in the crowded migraine market? Exton, PA., August 17, 2023 –In February 2023, Pfizer published their positive Phase 3 clinical trial results for zavegepant (new brand name, Zavzpret™). At the time, neurologists surveyed in a Spherix Global Insights study were “cautiously optimistic” that the first-ever, CGRP receptor […]
What’s on Your Must-Read List? If You Work in Pharma, Add Spherix Global Insights’ Generalized Myasthenia Gravis Patient Chart Audit to that List
US neurologists in Spherix’s in-house physician network complete a patient chart audit of over 600 patients with gMG. Exton, PA, August 10, 2023 – In one of the largest patient-focused studies ever conducted in gMG, Spherix’s RealWorld Dynamix™: Treatment Patterns in generalized Myasthenia Gravis not only illuminates critical aspects of patients’ presentation, diagnosis, and management […]
Breaking Into a Saturated Relapsing Remitting Multiple Sclerosis Market: Where Should Developers Focus?
According to Spherix Global Insights, U.S. neurologists are largely satisfied with current treatment choices in the RMS market, but opportunities remain. Exton, PA, August 1, 2023 – Despite outward appearances of being a stagnant market, the relapsing remitting multiple sclerosis market continues to offer drug developers opportunities to break in – if their new assets offer […]
First-to-Market Edge for Apellis’s Syfovre in Geographic Atrophy Diminished in the Face of an Unexpected Safety Signal
Prospects for Syfovre uptake and trust in Apellis take a plunge following reports of intraocular inflammation, according to Spherix Global Insights EXTON, Pa., July 28, 2023 – For many who have been following the retina market, the news about the emerging safety signal associated with Apellis’ Syfovre in geographic atrophy (GA) feels very similar to […]
Market Access Issues Hindering Specialists’ Use of Advanced Systemics in Lupus Nephritis
According to Spherix Global Insights, US Rheumatologists are taking increasing ownership over lupus nephritis (LN) patient management, yet they are more likely than nephrologists to express frustrations with payers’ restriction of LN drugs. EXTON, Pa., July 27, 2023 — While the approvals of GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have provided rheumatologists and nephrologists […]
Another win for Novo’s semaglutide? Physicians prefer it most in the emerging field of NASH treatments, survey finds
As fatty liver disease gets a new name, will it also finally get approved drug treatments? That’s what healthcare professionals are hoping for as nonalcoholic fatty liver disease (NAFLD) becomes metabolic dysfunction-associated fatty liver disease (MAFLD), and nonalcoholic steatohepatitis (NASH) becomes metabolic dysfunction-associated steatohepatitis (MASH). The name changes, aimed at getting rid of stigmatizing language […]
Akebia’s Vafseo (vadadustat) Poised to Make Waves for GSK’s Jesduvroq and FibroGen/Astellas’ Evrenzo
According to Spherix Global Insights and EU5 nephrologists are anticipating a more dynamic and competitive HIF-PH inhibitor market Exton, PA, July 20, 2023 – Nephrologists have long awaited the approval of HIF-PH inhibitors for the treatment of anemia in their chronic kidney disease (CKD) patients. While several agents within the class have found success globally, […]
A Call for Help from Physician Specialists on the Frontline Treating MASLD/MASH
Spherix Global Insights finds gastroenterologist and hepatologist capacity is being stretched to the limit by increasing demand from MASLD/MASH patients Exton, PA., July 17, 2023 – Data from the Centers for Disease Control & Prevention (CDC) suggests just over seventy percent of American adults are overweight, including 40% being clinically obese. Nearly twenty percent of […]
